Radiation and chemotherapy improve outcome in oligodendroglioma

Allison, Ron R.; Schulsinger, Alan; Vongtama, Vitune; Barry, Timothy; Shin, Kyu H.

doi:10.1016/s0360-3016(96)00452-x

Cited by 41 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Around two-thirds of AOs treated with chemotherapy show radiographic response, and the contrast with the poor chemosensitivity of astrocytic gliomas is borne out in one direct comparison between tumour groups. [95][96][97][98][99] The improved prognosis for AO patients with -1p/-19q chromosomal losses has been directly related to increased chemotherapy in a number of series, including radiographic evidence of objective tumour response. 17,25,26,30 Conversely, AOs with -10q are less likely to respond to chemotherapy.…”

Section: Radiotherapymentioning

confidence: 99%

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Garside¹,

Pitt²,

Anderson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Radiotherapymentioning

confidence: 99%

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Garside¹,

Pitt²,

Anderson³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Another issue in the treatment of patients with LGG is whether a combination of chemotherapy and RT is superior to RT alone [71]. A prospective trial by the Southwest Oncology Group addressed this question in 60 adult patients with incompletely resected LGGs.…”

Section: Chemotherapymentioning

confidence: 99%

Low-Grade Gliomas in Adults

2006

View full text Add to dashboard Cite

Low-grade gliomas are a heterogeneous group of neoplasms usually encountered in younger patient populations. These tumors represent a unique challenge because most patients will survive a decade or more and may be at a higher risk for treatment-related complications. Clinical observations over the years have identified a subset of low-grade gliomas that tends to manifest more aggressive clinical behavior and require earlier, more aggressive intervention. Clinical and molecular parameters may allow better assessment of prognosis and application of risk-adjusted management strategies that may include resection, radiation, or chemotherapy. Improved methods of long-term cognitive and functional assessment are desperately needed in this patient population.

show abstract

“…The majority of the available literature does indicate that radiotherapy prolongs patient survival, especially if the tumor has been partially resected. 2,34,40,71,[73][74][75] In children, radiation is withheld whenever possible. 2,50 Even in adults, because these patients experience a rel-…”

Section: Postoperative Treatmentmentioning

confidence: 99%

“…49,52,78,79,83,85 Patients undergoing both treatments have been reported to experience a longer survival than those treated with either modality alone. 2,79 As with radiotherapy, chemotherapy is associated with significant adverse effects. Side effects of PCV chemotherapy have been reported to include nausea, vomiting, anorexia, fatigue, rash, numbness or paresthesias, weakness, abdominal pain, constipation, neuropathy, hepatotoxicity, encephalopathy, seizures, intracranial hemorrhage, pneumonia and other infections, neutropenia, and thrombocytopenia.…”

Section: Neurosurg Focus / Volume 12 / February 2002mentioning

confidence: 99%

“…The authors of other studies have published similar results. 2,34,48,63,68 Despite the information available, it is difficult to predict survival for the individual oligodendroglioma patient on clinical grounds, given the following factors: 1) earlier diagnosis and improved surveillance provided by MR imaging; 2) rapid evolution in treatment taking place; and 3) possibility of conversion to an anaplastic tumor that is refractory to all treatments. …”

Section: Clinical Prognostic Factors Andmentioning

confidence: 99%

See 1 more Smart Citation

Current diagnosis and treatment of oligodendroglioma

Engelhard

2002

FOC

View full text Add to dashboard Cite

Object The strategies used to diagnose and treat oligodendroglial tumors have changed significantly over the past decade. The purpose of this paper is to review the topic of oligodendroglioma, emphasizing the new developments. Methods Information was obtained by conducting a Medline search in which the term oligodendroglioma was used. Recent editions of standard textbooks were also studied. Because of tools such as magnetic resonance imaging, oligodendrogliomas are being diagnosed earlier, and they are being recognized more frequently histologically than in the past. Seizures are common in these patients. Functional mapping and image-guided surgery may now allow for a safer and more complete resection, especially when tumors are located in difficult areas. Genetic analysis and positron emission tomography may provide data that supplement the standard diagnostic tools. Unlike other low-grade gliomas, patients in whom residual or recurrent oligodendroglioma (World Health Organization Grade II) is present may respond to chemotherapy. Although postoperative radiotherapy prolongs survival of the patient, increasingly this therapeutic modality is being delayed until tumor recurrence, especially if a gross-total tumor resection has been achieved. Oligodendrogliomas are the first type of brain tumor for which “molecular” characterization gives important information. The most significant finding is that allelic losses on chromosomes 1p and 19q indicate a favorable response to chemotherapy. Conclusions Whereas surgery continues to be the primary treatment for oligodendroglioma, the scheme for postoperative therapy has shifted, primarily because of the lesion's relative chemosensitivity. Molecular characterization of oligodendrogliomas may become a standard practice in the near future.

show abstract

Radiation and chemotherapy improve outcome in oligodendroglioma

Cited by 41 publications

References 10 publications

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

Low-Grade Gliomas in Adults

Current diagnosis and treatment of oligodendroglioma

Contact Info

Product

Resources

About